The Fibrinogen-to-Albumin Ratio has emerged as a potential risk predictor for patients with bladder cancer, oral cancer, gastrointestinal mesenchymal tumors, gastric cancer undergoing chemotherapy, IB-IIA cervical cancer, hepatocellular carcinoma, gallbladder cancer, and pancreatic cancer (25–32). This evidence concerns the gene ALB and lip and oral cavity carcinoma.